Tag: AFib

Study Demonstrates Cardiologs’ AI Can Predict Occurrence of Atrial Fibrillation in the Near Future

Newly published research shows that Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm. PARIS and BOSTON, June 21, 2022 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today that its latest study, “Short-term prediction of atrial […]

AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain […]

Kardium’s Globe® System Begins Clinical Trial at St. Paul’s Hospital

A revolutionary device that treats Atrial Fibrillation (AF) – the world’s most common heart rhythm disorder – helps support the healthy aging of BC’s population. April 12, 2022, 9:00 AM Pacific Daylight Time | VANCOUVER, British Columbia – Kardium Inc. announces a successful first-in-BC investigational* clinical procedure using the Globe® Mapping and Ablation […]

Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF

New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillation Additional data shows that Zio AT can positively impact hospital resources – saving one healthcare system 136 inpatient hospitalization days SAN FRANCISCO, April 03, 2022 (GLOBE NEWSWIRE) — iRhythm […]

AtriCure Publishes Inaugural ESG Report

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report highlighting the company’s corporate responsibility and sustainability initiatives. AtriCure’s 2021 ESG Report showcases several […]

Carta Healthcare Announces Distinction as an NCDR Certified Software Vendor for the American College of Cardiology’s (ACC) AFib Ablation Registry

Atlas, Carta Healthcare’s AI-assisted data abstraction solution, provides seamless, end-to-end submissions to the ACC’s AFib Ablation clinical data registry SAN FRANCISCO–(BUSINESS WIRE)–Carta Healthcare, provider of solutions for common healthcare data challenges through a combination of people, processes, and artificial intelligence (AI)–powered technology, today announced that it is now a National […]

Adagio Medical Announces Successful First-In-Human Cases of Pulsed Field Cryoablation for Treatment of Atrial Fibrillation

LAGUNA HILLS, Calif., Jan. 4, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced first-in-human cases of pulsed field cryoablation (PFCA) for the treatment of atrial fibrillation (AF). The cases were performed at Medicover Hospital, Warsaw, Poland by Dr. Pawel Derejko, Head […]

Affera Announces First Patient Treated in SPHERE Per-AF IDE Trial

First enrollment comes as investors provide $75M toward an oversubscribed Series C financing NEWTON, Mass., Dec. 20, 2021 /PRNewswire/ — Affera Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced today that the first patient was treated in the recently approved SPHERE PerAF Trial, a U.S. Food and […]

Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication

ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism.” This multi-center, prospective study […]

Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment

U.S. Food and Drug Administration approval of a clinical trial of Cardialen’s low-energy defibrillation and cardioversion therapy expands the number of leading clinical institutions evaluating its promising MultiPulse™ Therapy. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a […]